Zyloric

Quick links to important sections

Zyloric

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zyloric

Property Description
Active ingredient Allopurinol
Form Oral Tablet
Pharmacological class Xanthine Oxidase Inhibitor (XOI)
Common purpose Management of hyperuricemia (high uric acid)
Origin Synthetic

What is Zyloric and Its Active Ingredient?

Zyloric is a prescription-only medication designed to manage conditions that result from the body producing too much uric acid, a state referred to as hyperuricemia. The drug's core chemical identity is its single active ingredient, Allopurinol (INN), which is included on the World Health Organization Model List of Essential Medicines. Allopurinol is clinically recognized as a standard, first-line treatment for chronic gout.

Allopurinol is classified as a Xanthine Oxidase Inhibitor (XOI), which places it in the broader therapeutic category of antigout agents. It is a synthetic compound, specifically a pyrazolopyrimidine derivative, that acts systemically. Unlike treatments focused solely on acute inflammation, Zyloric is positioned as a foundational maintenance therapy for patients with chronic urate imbalance. The standard presentation for maintenance therapy is an Oral Tablet, although it is also available as a Powder for Injection for specialized intravenous use in certain clinical settings.


How Does Zyloric Control Uric Acid Levels?

The fundamental purpose of Zyloric is to ensure the reduction of uric acid production within the body, which helps prevent the complications of high levels. It achieves this by acting as a direct obstacle to the enzyme xanthine oxidase. This mechanism is a recognized pharmacological action of the drug.

This mechanism of inhibition of xanthine oxidase means the drug prevents the final steps in the purine catabolism pathway, where precursor substances are converted into uric acid. By slowing this production, Zyloric's action leads to a sustained decrease in the concentration of uric acid in the blood. This control is critical for preventing the formation and deposition of painful monosodium urate crystals throughout the joints and tissues, providing foundational management for hyperuricemia.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Zyloric?

Possible Side Effects and Safety Information

The safety profile of Allopurinol (Zyloric) is officially classified by frequency bands in regulatory documents, defining the likelihood of documented adverse reactions. These effects are grouped into System-Organ Classes (SOCs), providing a clear overview of which body systems may be affected.

Frequency-Based Adverse Reactions

The most Common reactions (observed in 1% to 10% of patients) primarily involve the Skin and Subcutaneous Tissue Disorders, manifesting as a rash. This dermatological reaction is often noted in regulatory labeling to occur at the initiation of therapy or during periods of dose increase.

Uncommon reactions (observed in 0.1% to 1% of patients) include generalized hypersensitivity reactions, alongside effects on the Gastrointestinal System, such as nausea and vomiting. An increase in liver function test values is also classified in this category.

Serious Safety Considerations

The medicine is associated with Very Rare (less than 0.01%) but serious reactions. These include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Other serious reactions classified as very rare involve the Blood and Lymphatic System Disorders, manifesting as changes in blood cell counts (e.g., blood dyscrasias), and the occurrence of acute renal failure.

Population-Specific Notes

Official safety documentation includes specific notes regarding use in compromised populations. Safety considerations are explicitly addressed for individuals with pre-existing Renal Impairment and Hepatic Impairment, as these conditions can influence the drug's safety profile.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is based strictly on governmental regulatory documents (e.g., FDA Prescribing Information and EMA Summaries of Product Characteristics) for the active ingredient, Allopurinol, and is not medical advice.


Documented Overdose Manifestations and Severe Outcomes

Single-dose ingestions of Allopurinol of up to 22.5 g have been reported. The officially documented manifestations of overdose include nausea, vomiting, diarrhea, dizziness, headache, stomach pain, and tiredness.

The most serious complication of allopurinol overdose is the potential for severe impaired renal function that can progress to acute renal failure. Massive ingestions have been documented as resulting in acute renal failure, which can be fatal. Since the drug and its active metabolite are cleared by the kidneys, existing impaired renal function is a critical factor in overdose severity.


Official Emergency Actions

In the event of a suspected or known overdose, immediate medical attention is required. Regulatory documents mandate that individuals seek emergency medical attention or call a Poison Help line immediately. In the U.K., this is equivalent to contacting 111 or calling 999 for emergency services.

No specific antidote to allopurinol is known. Official management focuses on supportive treatment, which may include measures such as adequate hydration, gastric lavage, and haemodialysis to help remove the drug and its metabolites from the body.

Therapeutic Uses of Zyloric

Zyloric is generally used in situations involving certain distressing symptoms. It provides long-term support for conditions presenting with systemic or localized discomfort. This medication is applied across domains where additional symptomatic support is needed, for conditions involving episodic or fluctuating manifestations, conditions involving inflammatory or irritative processes, and clinical settings marked by increased discomfort or tension.


Supporting Comfort and Stability

Zyloric is commonly used across conditions presenting with acute episodes, primarily to manage the overall symptom burden of conditions characterized by periods of heightened symptoms. It helps address symptom clusters that may become intense or disruptive, offering supportive relief that may contribute to easing the overall symptom load. The medicine is also applied in clinical settings that involve acute or unstable symptom patterns, such as during phases when symptoms become more noticeable due to heightened systemic burden. It is often used when symptoms intensify and supportive relief is needed.

“Applied across domains where additional symptomatic support is needed to address systemic discomfort.”

Zyloric is relevant for easing recurrent or episodic manifestations where functional stability may become affected, and assists with maintaining functional stability.


Quick Fact: Supportive Symptom Management Zyloric is relevant when supportive symptom management is appropriate and is applied in scenarios where additional management of discomfort is required.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Zyloric (allopurinol) use is defined by regulatory bodies through specific contraindications and required precautions based on a patient's clinical status, genetic background, and age.

Contraindicated Populations

  • Hypersensitivity: Individuals with a known allergy or severe reaction to allopurinol or any component of the formulation must not use this medicine.
  • Breastfeeding: Use is contraindicated or not recommended in women who are breastfeeding.
  • Acute Gout Attack: Treatment initiation must be withheld until a current acute gouty attack has completely subsided.

Populations Requiring Restricted or Conditional Use

Population/Condition Eligibility Status Restriction/Condition (Based on Official Labeling)
Renal (Kidney) Impairment Restricted Use Requires reduced doses and careful monitoring; the risk of hypersensitivity may be increased.
Hepatic (Liver) Impairment Restricted Use Requires reduced doses and periodic liver function tests.
Han Chinese, Thai, or Korean Origin Restricted Use Requires extra vigilance due to a significantly increased risk of severe skin reactions (SJS/TEN), often linked to the HLA-B*58:01 allele.
Pregnancy Not Recommended Generally not recommended unless the potential benefits are clearly justified by the prescribing physician.
Children under 15 Rarely Indicated Use is rarely indicated, primarily reserved for certain malignancies (e.g., leukemia) or inborn errors of metabolism (e.g., Lesch-Nyhan syndrome).

What should I know about interactions with other medicines?

The official regulatory profile for allopurinol focuses on its documented effect on the metabolism and clearance of co-administered medicines. The most significant interaction involves the purine analogues Mercaptopurine and Azathioprine, whose enzymatic inactivation is blocked. This pharmacokinetic interaction leads to toxic serum concentrations and a risk of fatal myelosuppression, mandating that the combination be avoided or that the purine analogue dose be reduced to one-quarter. Therapy with Pegloticase requires allopurinol to be discontinued and not instituted during treatment.

Interactions also affect drug clearance and safety. Co-use with Thiazide Diuretics is documented to increase the occurrence of hypersensitivity reactions, a risk that is specifically heightened in patients with decreased renal function. Co-administration with Ampicillin or Amoxicillin is associated with an increased frequency of skin rash.

The effect on clearance involves Uricosuric agents and large dose Salicylates, which accelerate the excretion of the active metabolite, Oxipurinol, potentially reducing efficacy. To prevent an attenuated therapeutic effect, antacids containing Aluminium Hydroxide require a mandatory 3-hour interval separation. The metabolism of Theophylline is inhibited, requiring plasma concentration monitoring, and Coumarin Anticoagulants may exhibit an increased effect.

Mechanism of Action

Targeted Inhibition of Uric Acid Production

Zyloric’s core mechanism is the precise inhibition of Xanthine Oxidase (XO), the enzyme responsible for the final steps of purine catabolism. The drug is a structural analog that blocks the XO enzyme, significantly reducing its capacity to convert the purine bases Hypoxanthine and Xanthine into Uric Acid. This direct molecular blockage limits the production of Uric Acid at its source.


The Dual-Action Mechanism and Pathway Rerouting

The drug’s action is maintained by its active metabolite, Oxypurinol, which is formed in the body and binds tightly to the XO enzyme. This dual-action mechanism provides consistent inhibition of the enzyme, which reduces the systemic Uric Acid concentration. By rerouting the metabolic pathway, the drug causes the more soluble precursors (Hypoxanthine and Xanthine) to be excreted.


Physiological Consequence: Crystal Equilibrium

The resulting physiological effect of continuously lowered Uric Acid concentration is a shift in the body’s chemical equilibrium. This shift creates the necessary chemical gradient for the release of Monosodium Urate material from tissue deposits. The inhibition also secondarily reduces the production of reactive oxygen species generated by XO, thereby limiting a source of cellular oxidation.

Dosage and Administration Information

How Zyloric Is Used: Official Administration Guidelines

Zyloric (allopurinol) is administered primarily as an oral tablet for long-term chronic management, which is the foundational route of therapy. An intravenous (IV) injection is also an approved route for use in specialized hospital settings, specifically for hyperuricemia related to cancer treatment.

Oral therapy begins with a low starting dose, typically 100 mg once daily. The dose is then gradually titrated (increased) in 100 mg increments at weekly intervals until the necessary maintenance level is achieved. Daily doses exceeding 300 mg must be given in divided administrations to aid gastrointestinal tolerability.

Tablets should be taken following a meal or with food to minimize gastric irritation. Furthermore, patients are instructed to maintain a high daily fluid intake to yield a urinary output of at least two liters to facilitate proper urate elimination. A mandatory dose reduction is required for patients with impaired kidney function, with the specific daily dose determined by the patient’s creatinine clearance. For hyperuricemia associated with chemotherapy, administration must be initiated 24 to 48 hours prior to the start of the cytotoxic regimen, serving as a pre-treatment measure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zyloric

Evidence for Management of Chronic Gout and Hyperuricemia

The foundation of evidence for Zyloric (allopurinol) involves numerous randomized controlled trials (RCTs) and meta-analyses that explored the clinical situation of high uric acid (hyperuricemia) and gout. Research examined its use in contexts that continuously examined treatment, often compared against placebo or other therapies studied for this clinical situation, in adults. Researchers primarily focused on measuring shifts in serum urate (sUA) concentration, tracking if the levels moved toward lower targets relevant in studies assessing the condition's progression. Studies also monitored the frequency of gout flares and changes in the size of tophi (urate deposits). Data for certain groups, particularly those with complex co-existing health issues, appears to be limited.

Evidence for Specific Clinical Uses

Research has also explored Zyloric for two other specific clinical scenarios. It was examined in a short-term context for the risk of acute uric acid elevation in oncology patients (Tumor Lysis Syndrome prophylaxis), where studies monitored changes in uric acid levels and the occurrence of acute kidney injury following chemotherapy. Separately, research has explored whether Zyloric was associated with outcomes in individuals who repeatedly form calcium oxalate kidney stones who also exhibit high levels of uric acid in their urine (hyperuricosuria). In these stone prevention studies, researchers tracked the recurrence rate of kidney stones and reduction of excess uric acid in the urine.

Long-term Outcomes and Uncertainty

While numerous studies provide insight into short-term changes related to uric acid control, there is limited information for long-term outcomes regarding sustained effects over many years. Follow-up durations were limited in initial trials, offering limited information for outcomes that take years to characterize, such as long-term joint outcomes or kidney function measurements. Comparative evidence remains limited regarding the use of Zyloric against all available alternative urate-lowering therapies across every severity level, and certainty remains low for outcomes not directly related to gout.

Frequently Asked Questions (FAQ)

Common questions about Zyloric (FAQ)


Q: Can Zyloric be taken every day for a long time?

A: Yes, regulatory documents indicate that Zyloric (allopurinol) is intended for the chronic management of hyperuricemia and gout. This means it is designed to be taken long-term as a daily maintenance therapy to help control uric acid levels in the body.

Q: Can Zyloric cause a rash?

A: A rash is a commonly reported adverse reaction listed in the official product information. This reaction is sometimes described as presenting as flat lesions or small raised lesions on the skin. This possibility is noted in official documentation, particularly when initiating treatment.

Q: Is it common to feel stomach upset when starting Zyloric?

A: Official information advises taking the tablets after meals to help minimize gastric irritation. While nausea and vomiting are listed as possible adverse reactions, they are generally considered uncommon side effects.

Q: Is there a list of medicines to avoid while taking Zyloric?

A: Official prescribing information highlights specific significant interactions. Medicines like Mercaptopurine, Azathioprine, and Pegloticase are examples of drugs whose combination with Zyloric may require dose reduction or avoidance due to the potential for significant adverse outcomes.

Q: How is Zyloric different from other gout medications?

A: Zyloric is classified as a Xanthine Oxidase Inhibitor (XOI). Its mechanism is to inhibit the formation of uric acid in the body. This is distinct from other types of gout medications, such as uricosuric agents, which work by increasing the excretion of uric acid through the urine.

Q: Can Zyloric interact with natural or herbal supplements?

A: Authoritative bodies note that there is limited available information from clinical research and regulatory sources regarding the safety of taking Zyloric with herbal remedies, supplements, or complementary medicines.

Q: Can Zyloric be crushed or split?

A: The official labeling does not explicitly address the physical alteration of the tablet (such as crushing or splitting). However, administration advice indicates that higher daily doses should be given in divided doses.

Q: What Zyloric is used to treat besides gout?

A: In addition to chronic gout, Zyloric is indicated for the management of high uric acid levels that occur following certain cancer treatments (known as Tumor Lysis Syndrome prophylaxis). It is also approved for managing recurrent calcium oxalate kidney stones when associated with high urinary uric acid.

Q: How quickly does Zyloric start to work for gout?

A: According to the official product information, administration generally results in a fall in both blood and urinary uric acid within two to three days. However, it may take a week or more of continued treatment for the full therapeutic effects to be observed.

Q: Does Zyloric interact with common over-the-counter medications?

A: Official information notes potential interactions with certain substances sometimes found in over-the-counter products. These include Salicylates (like aspirin) and antacids containing Aluminium Hydroxide.

Q: Can Zyloric affect blood pressure?

A: Regulatory monitoring guidelines advise that blood pressure should be monitored in patients who have concurrent conditions, such as hypertension. Effects on blood pressure are not typically listed as a common side effect in official adverse reaction frequency charts.

Q: Why is Zyloric sometimes prescribed for certain types of cancer treatment?

A: The medicine is used to help prevent or lower high uric acid levels that can rapidly build up after certain cancer treatments (chemotherapy). This use is known as prophylaxis for Tumor Lysis Syndrome.

Q: Do doctors ever prescribe Zyloric for asymptomatic hyperuricemia?

A: Official regulatory documents indicate that asymptomatic hyperuricemia (high uric acid levels without physical symptoms) per se is generally not considered an indication for the use of Zyloric.

Q: Are there any specific dietary restrictions when taking Zyloric?

A: Official labeling states that clinical experience suggests that patients may benefit from dietary changes in addition to drug therapy. However, no specific restrictions are formally mandated in the official product information.

Q: Does taking Zyloric mean I can stop watching my diet for gout?

A: Official guidelines advise that dietary changes are often recommended in addition to drug therapy. This suggests that diet remains a relevant factor in the overall long-term management of the condition.

Q: Why does Zyloric sometimes cause more gout flares when you first start taking it?

A: Regulatory documents report that an increase in acute attacks of gout has been observed during the early stages of administration. This may occur even after a decrease in serum uric acid levels has been measured.

Q: Can Zyloric cause joint pain as a side effect?

A: Joint pain, often affecting the great toe, ankle, or knee, as well as joint stiffness or swelling, are listed in detailed side effect profiles derived from regulatory data as more common adverse reactions.

Q: Is Zyloric a common cause of drug interactions?

A: Regulatory data indicates that there are many drugs known to interact with allopurinol. A large number of these interactions are classified as clinically significant.

Q: Do I need to get blood tests while taking Zyloric?

A: Monitoring of certain laboratory parameters is often recommended, which may include periodic checks of renal function, liver function tests, complete blood count (CBC), and serum uric acid levels.

Q: Is Zyloric used for kidney stones?

A: Yes, Zyloric is indicated for the management of recurrent mixed calcium oxalate kidney stones when that condition is associated with high uric acid in the urine (hyperuricosuria).

Q: Does Zyloric cause fatigue or tiredness?

A: Official adverse reaction profiles list drowsiness, somnolence, and unusual tiredness or weakness as possible side effects that have been reported by some patients.

Q: What if I forget to take my Zyloric dose?

A: Official administration advice on a missed dose indicates that a double dose should not be taken at the next scheduled time. The next dose should instead be taken as regularly scheduled.

Q: Does Zyloric cause hair loss?

A: Detailed side effect profiles derived from regulatory data list hair loss or thinning of the hair as a rare adverse reaction.

Q: What is the recommended fluid intake when on Zyloric?

A: Official labeling references the importance of maintaining a fluid intake that results in a daily urinary output of at least 2 liters. This is mentioned to facilitate the proper elimination of urate from the body.

Q: What happens if Zyloric is taken past its expiration date?

A: Official patient information advises that the medicine should not be taken after the expiration date printed on the packaging. Using expired medication carries the risk that it may have no effect or an unexpected effect.

Q: Is there a generic version of Zyloric available?

A: Yes, the active ingredient in Zyloric is allopurinol, which is the generic name for the substance. The product is marketed and formulated by several different manufacturers.

Q: Is it safe for older adults (seniors)?

A: Official administration advice notes that caution is recommended when determining the appropriate dose for older adults. Regulatory guidelines state that dose adjustments may be required in this population.

Q: Is it safe to drive after taking Zyloric?

A: Official warnings state that drowsiness, somnolence, and dizziness have been reported as side effects. These effects suggest a potential to impact a patient's ability to drive or safely use machinery.

How should Zyloric be stored and disposed of?

How to Store and Dispose of Zyloric?

Zyloric (allopurinol) tablets must be stored according to specific regulatory conditions to maintain stability and safety.

Storage Requirements

The tablets should be stored at controlled room temperature, specifically not above 25 C (77 F). The product must be kept in the original container, tightly closed, and stored away from excess heat and moisture. It is mandatory to keep this medicine out of the sight and reach of children.

Disposal Instructions

Expired or unused Zyloric tablets must not be disposed of via wastewater or household trash. Official instructions require users to return unwanted medicine to a pharmacist for proper disposal. Disposal methods must adhere to local and national regulations to avoid release into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zyloric found in:

A-Z Index: